In a blunt assessment of the German biotech’s situation after reporting earnings for the first half of the year, CEO Christian Wojczewski, Ph.D., said revenues and profitability for the six-month period “have been more challenging for the company than expected.”
https://www.fiercebiotech.com/biotech/evotec-eyes-400-layoffs-citing-challenging-market